Quarry LP Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Quarry LP lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 117.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,997 shares of the medical research company's stock after acquiring an additional 3,786 shares during the quarter. Quarry LP's holdings in Edwards Lifesciences were worth $518,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $610,895,000. Jennison Associates LLC bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $555,939,000. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $213,844,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.69 during mid-day trading on Friday, hitting $75.87. The company had a trading volume of 1,717,748 shares, compared to its average volume of 5,000,408. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $44.60 billion, a price-to-earnings ratio of 10.89, a P/E/G ratio of 4.82 and a beta of 1.15. The company's fifty day moving average is $71.08 and its 200-day moving average is $71.26. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 earnings per share. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent research reports. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $79.45.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,853 shares of company stock worth $5,163,062 over the last three months. Insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.